logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for global professionals · Friday, March 6, 2026 · 897,579,880 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Companies News  •••  Topics  •  Countries  •  U.S. States

Biocon Patent News Monitoring

  • Published on Mar 3, 2026

    Genentech Says Biocon Importing Infringing Cancer Drugs

    By Jack McLoone ( March 3, 2026, 3:45 PM EST) -- Biotechnology company Genentech Inc. claimed Indian firm Biocon Ltd. is importing drugs into the U.S. that infringe four Genentech patents related to a breast cancer treatment, asking the U.S. International …

    Source: Law360 - Pending
  • Published on Feb 13, 2026

    Biocon to weigh pricing dynamics for advancing semaglutide generic in India

    New Delhi: Drugmaker Biocon will assess the pricing dynamics of India’s burgeoning anti-obesity market before advancing its semaglutide generic development and potential launch, as the impeding entry of its domestic peers likely to bring significant price …

    Source: ETPharma.com - Pending
  • Published on Feb 13, 2026

    Biocon aims for revenue surge with rollout of generic weight-loss drugs

    Audio By Carbonatix By Rishika Sadam Feb 13 (Reuters) – Biocon is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about …

    Source: SRN News - Center-right
  • Published on Feb 14, 2026

    Biocon nears full integration of biologics arm after Mylan buyback

    The Bengaluru-based company on 14 January said it raised ₹4,150 crore ($460 million) through a qualified institutional placement (QIP) of shares to buy out Mylan Inc’s (Viatris) stake in the subsidiary. Days later, it announced it had completed the …

    Source: Mint - Neutral
  • Published on Feb 9, 2026

    Semaglutide: What happens when patent expires?

    Who invented Semaglutide — and how it works Semaglutide was developed by Novo Nordisk, the Danish pharmaceutical company long known for its dominance in diabetes care. It belongs to a class of drugs called GLP-1 receptor agonists, which mimic a naturally …

    Source: Gulf News - Gov't Propaganda
  • Published on Feb 8, 2026

    India’s Semaglutide Patent Expiry Sparks Global Generic Drug Boom

    Every morning in Shivaji Park in Mumbai, people gather for power walking along the running tracks, and their fitness watches log every step. After the workout, some visitors approach the neighboring food kiosks: oil sizzles, hot samosas, and syrupy jalebi …

    Source: Mezha - Indeterminate
  • Published on Feb 26, 2026

    Brazilian Drugmakers Seek Indian Technology to Manufacture Weight-Loss Injection Pens

    With the expiration of Ozempic’s patent in March 2026 approaching, Brazilian pharmaceutical companies Biomm and Amoveri joined a government delegation to India to sign technology transfer agreements. The goal is to begin domestic production of weight-loss …

    Source: Folha de Sao Paulo - Center-left
  • Published on Feb 24, 2026

    Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide

    Mumbai: Eris Lifesciences has tied up with Hyderabad-based Natco Pharma to commercialise semaglutide, ahead of the blockbuster weight-loss drug’s patent expiry. The partnership comes on the heels of Natco receiving regulatory approval from the Central …

    Source: Mint - Neutral
  • Published on Feb 28, 2026

    Abbott Bets On Semaglutide Boom

    Abbott will be the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma. IMAGE: Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs made by Novo Nordisk and Lilly. …

    Source: Rediff - Center-right
  • Published on Feb 26, 2026

    Women in science: catalysing Viksit Bharat – It is really much more ...

    National Science Day Special –February 28 Upasana Bora Sinha In 1930, Sir C.V. Raman, one of India’s most eminent physicists was awarded the Nobel Prize in Physics for his outstanding discovery on the scattering of light, which is commonly known as the “ …

    Source: The Morung Express - Neutral
  • Published on Feb 24, 2026

    NATCO pacts with Eris to market semaglutide generic in India

    Mumbai: Hyderabad-based NATCO Pharma has out-lisensed its semaglutide generic formulation India market rights to Ahmedabad-based Eris Lifesciences. Without disclosing the deal financial terms, in a release Eris stated to have inked a strategic partnership …

    Source: ETPharma.com - Pending
  • Published on Feb 19, 2026

    Zydus launches Aflibercept biosimilar in India

    Ahmedabad: Zydus Lifesciences has announced the launch of its blockbuster therapy aflibercept biosimilar version in India. The commercial launch is announced following an agreement with the drug’s patent owner Regeneron Pharmaceuticals, and Bayer, …

    Source: ETPharma.com - Pending
  • Published on Feb 23, 2026

    A passage to India: How America’s visa chaos may spark the next tech boom in India

    Selva’s decision reflects a broader rethink among specialized tech hands. From the Indian Institutes of Technology (IITs) to tier-II colleges, generations of engineers built their dreams around a US visa, a job in Silicon Valley, and the promise of global …

    Source: Mint - Neutral
  • Published on Feb 10, 2026

    ‘We fought monopoly, not science’: Pharma leaders debate India’s future

    “We fought against monopoly, not science,” said Dr Yusuf Hamied of Cipla, recalling how Indian drugmakers campaigned for the Patents Act of 1972. He described telling then Prime Minister Indira Gandhi that Indians should not be denied propranolol, a life- …

    Source: The Indian Express - Center-left
  • Published on Feb 19, 2026

    Dr Reddy’s plans 'beyond-the-pill' strategy for Semaglutide

    Dr Reddy’s Laboratories is positioning itself for a long-term strategy in obesity and metabolic therapies, developing a broader GLP-1 pipeline and building a support ecosystem even as it prepares for a Day 1 launch of generic semaglutide in India. The …

    Source: Business Today - Indeterminate
  • Published on Feb 18, 2026

    Pharma Chiefs on Ripening R&D Bets in India and the Road to Returns

    Hyderabad: Translating laboratory promise into commercial payoff has long been pharma’s core survival fuel, repeatedly testing business models and balance sheets across global markets. For India, the shift from short-term generics gains to long-term, cycle …

    Source: ETPharma.com - Pending
  • Published on Feb 4, 2026

    Chasing cost: Cancer care toxicity and the hope from Biosimilars

    New Delhi: “I have to atone for my sins,” a physician from Chennai in 2007 told Dr. Mammen Chandy, India’s leading voice in Hemato-oncology and the man who performed the country’s first bone marrow transplant. The doctor was reflecting on his past, haunted …

    Source: ETPharma.com - Pending
  • Published on Feb 10, 2026

    Zydus sees first-to-market Opportunity with Keytruda biosimilar

    New Delhi: Zydus Lifesciences expects its in-licensed Keytruda (pembrolizumab) biosimilar from Formycon AG to advance as the leading candidate across the industry and potentially be the first to enter the US market, subject to regulatory approvals. …

    Source: ETPharma.com - Pending
  • Published on Feb 7, 2026

    Simply Put: Biopharma Shakti

    Bhuvan and Sam are sharing views on the Budget announcements and Sam wants to know more about the Biopharma Shakti plan. As Bhuvan tracks pharma, Sam fires away at the topic. Sam: Biopharma Shakti, a plan to develop India as a biopharmaceutical hub has …

    Source: The Hindu Business Line - Neutral

03 days 19:48:48

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
search news using your own keywords. There are 897,579,880 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Companies A-Z >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 02/12/2026

World Media Directory >

Companies Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Companies Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Company News Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow EIN Presswire on Facebook, LinkedIn and Substack

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2026 Newsmatics Inc. · All Rights Reserved · General Terms & Conditions · Privacy Policy · Cookie Settings

By continuing to use this site, you agree to our Terms & Conditions, last updated on September 30, 2025.